4.7 Article

Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity

期刊

ANNALS OF SURGICAL ONCOLOGY
卷 9, 期 1, 页码 48-56

出版社

SPRINGER
DOI: 10.1245/aso.2002.9.1.48

关键词

brachytherapy; soft tissue sarcoma; extremity; high grade

资金

  1. NCI NIH HHS [CA-47179] Funding Source: Medline
  2. NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Background: We reviewed single-institution experience using brachytherapy alone for primary high-grade soft tissue sarcoma of the extremity. Methods: Between July 1982 and September 1997, 202 adult patients with primary high-grade soft tissue sarcoma of the extremity were treated with limb-sparing surgery and adjuvant brachytherapy. All patients underwent complete gross resection, but the margin of resection was microscopically positive in 18% of patients. The median dose of brachytherapy was 45 Gy delivered over 5 days. Tumors located in the shoulder or groin were defined as central location. Complications were assessed in terms of wound complications, bone fracture, and peripheral nerve damage. Results: With a median follow-up of 61 months, the 5-year local control, distant relapse-free survival, and overall survival rates were 84%, 63%, and 70%, respectively. On multivariate analysis, poor local control correlated with shoulder location, positive microscopic margins of resection, and nonshoulder upper extremity site. The 5-year actuarial rates of wound complications requiring reoperation, bone fracture, and grade greater than or equal to3 nerve damage were 12%, 3%, and 5%, respectively. Conclusions: Adjuvant brachytherapy provides adequate local control and acceptable morbidity that compares favorably with data reported for external beam radiation. Shoulder tumor location was identified as an independent prognostic factor for poor local control. mandating further improvement in the local management of these tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据